Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan

References

• The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Blood Press 2007; 16: 135–232
   PubMedGoogle Scholar
• Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., Jr., et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and treatment of High Blood Pressure: National High Blood Pressure education Program Coordinating Committee. JAMA 2003; 289: 2560–2572
   PubMed Web of Science ®Google Scholar
• Turnbull F., Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure‐lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomised trials. Lancet 2003; 362: 1527–1535
   PubMed Web of Science ®Google Scholar
• Turnbull F., Neal B., Algert C., Chalmers J., Chapman N., Cutler J., , Blood Pressure Lowering Treatment Trialists' Collaboration, et al. Effects of different blood pressure lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 2005; 165: 1410–1419
   PubMed Web of Science ®Google Scholar
• Weber M. A., Julius S., Kjeldsen S. E., Brunner H. R., Ekman S., Hansson L., et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–2051
   PubMed Web of Science ®Google Scholar
• Berl T., Hunsicker L. G., Lewis J. B., Pfeffer M. A., Porush J. G., Rouleau J. L., , The Collaborative Study Group, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16: 2170–2179
   PubMed Web of Science ®Google Scholar
• Dahlöf B., Sever P. S., Poulter N. R., for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo‐Scandinavian Cardiac Outcomes Trial‐Blood Pressure Lowering Arm (ASCOT‐BPLA); A multicentre randomised controlled trial. Lancet 2005; 366: 895–906
   PubMed Web of Science ®Google Scholar
• Julius S., Kjeldsen S. E., Weber M., for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 2004; 363: 2022–2031
   PubMed Web of Science ®Google Scholar
• Dahlöf B., Devereux R. B., Kjeldsen S. E., Julius S., Beevers G., de Faire U., , LIFE Study Group, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995–1003
   PubMed Web of Science ®Google Scholar
• Lewis E. J., Hunsicker L. G., Clarke W. R., Berl T., Pohl M. A., Lewis J. B., , Collaborative Study Group, et al. Renoprotective effect of the angiotensin‐receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860
   PubMed Web of Science ®Google Scholar
• Parati G., Omboni S., Malacco E., on behalf of the Study Group. Antihypertensive efficacy of zofenopril and hydrochlorothiazide combination on ambulatory blood pressure. Blood Press 2006; 15: 7–17
   Google Scholar
• Zanchetti A., Parati G., Malacco E. Zofenopril plus hydrochlorothiazide: Combination therapy for the treatment of mild to moderate hypertension. Drugs 2006; 66: 1107–1115
   PubMed Web of Science ®Google Scholar
• Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press 2007; 16 Suppl: 25–30
   Google Scholar
• Mallion J‐M. An evaluation of the initial and long‐term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press 2007; 16 Suppl: 13–18
   Google Scholar
• Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press 2007; 16 Suppl: 19–24
   Google Scholar
• Ambrosioni E., Borghi C., Magnani B., for the Survival of Myocardial Infarction Long‐Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin‐converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. New Engl J Med 1995; 332: 80–85
   PubMed Web of Science ®Google Scholar
• Borghi C., Ambrosioni E., Magnani B. Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. The SMILE Study Investigators. Survival of Myocardial Infarction Long‐term Evaluation. Am J Cardiol 1996; 78: 317–322
   PubMed Web of Science ®Google Scholar
• Borghi C., Bacchelli S., Esposti D. D., Bignamini A., Magnani B., Ambrosioni E. Effects of the administration of an angiotensin‐converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long‐term Evaluation. Am J Hypertens 1999; 12: 665–672
   PubMed Web of Science ®Google Scholar
• Borghi C., Ambrosioni E., Survival of Myocardial Infarction Long‐term Evaluation‐2 Working Party. Double‐blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long‐term Evaluation‐2 (SMILE‐2) study. Am Heart J 2003; 45: 80–87
   Google Scholar
• Lindholm L. H., Ibsen H., Dahlof B., Devereux R. B., Beevers G., de Faire U., , LIFE Study Group, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 1004–1010
   PubMed Web of Science ®Google Scholar
• Kjeldsen S. E., Westheim A. S., Os I. Prevention of cardiovascular events and diabetes with angiotensin‐receptor blockers in hypertension: LIFE, SCOPE, and VALUE. Curr Hypertens Rep 2005; 7: 155–157
   PubMedGoogle Scholar
• Yavuz D., Koc M., Toprak A., Akpinar I., Velioglu A., Deyneli O., et al. Effects of ACE inhibition and AT1‐receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone Syst 2003; 4: 197–203
   PubMed Web of Science ®Google Scholar
• Tikkanen I., Omvik P., Jensen H. A. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343–1351
   PubMed Web of Science ®Google Scholar